PT  - JOURNAL ARTICLE
AU  - Kim A. Papp
AU  - Boulos Haraoui
AU  - Deepali Kumar
AU  - John K. Marshall
AU  - Robert Bissonnette
AU  - Alain Bitton
AU  - Brian Bressler
AU  - Melinda Gooderham
AU  - Vincent Ho
AU  - Shahin Jamal
AU  - Janet E. Pope
AU  - A. Hillary Steinhart
AU  - Donald C. Vinh
AU  - John Wade
TI  - Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary
AID  - 10.3899/jrheum.180784
DP  - 2019 Jul 01
TA  - The Journal of Rheumatology
PG  - 751--754
VI  - 46
IP  - 7
4099  - http://www.jrheum.org/content/46/7/751.short
4100  - http://www.jrheum.org/content/46/7/751.full
SO  - J Rheumatol2019 Jul 01; 46
AB  - The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.